ArticleBMC musculoskeletal disorders2025
Serum miR-576-5p as a novel diagnostic biomarker and therapeutic target for osteoarthritis via targeting KLF10-mediated chondrocyte dysfunction.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Endocrine‑metabolic imbalance drives osteoarthritis: From whole‑joint pathobiology to precision therapy (Review).International journal of molecular medicine · 2026Review
- Inflammaging and immunosenescence-driven remodeling of the immune microenvironment in osteoarthritis: mechanisms, immune regulation and immune reprogramming.Frontiers in immunology · 2026Review
- MicroRNAs as Key Regulators of Degeneration and Inflammation in Osteoarthritis: A Narrative Review.Saudi journal of medicine & medical sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage breakdown, and currently lacks effective biomarkers and disease-modifying therapies. Dysregulated microRNAs (miRNAs) have been implicated in OA pathogenesis. This study explores the diagnostic potential and functional mechanism of miR-576-5p in OA.
methodsSerum levels of miR-576-5p were measured in 61 OA patients and 60 healthy controls (HC) using qRT-PCR. Diagnostic performance was assessed using ROC analysis. An in vitro model of chondrocyte injury was established by treating the human chondrocyte cell line C-28/I2 with IL-1β. The effects of miR-576-5p on cell viability, apoptosis, and inflammatory response were evaluated. Bioinformatic predictions and dual-luciferase reporter assays were used to identify Krüppel-like factor 10 (KLF10) as a target of miR-576-5p. Rescue experiments were conducted to confirm the functional interaction between miR-576-5p and KLF10.
resultsOA patients exhibited significantly lower serum miR-576-5p levels than HC, with an AUC of 0.886. Low miR-576-5p expression correlated with higher KL grades, WOMAC/VAS scores, and elevated CRP/CTX-II/COMP levels. In IL-1β-stimulated chondrocytes, miR-576-5p was downregulated, leading to decreased viability, increased apoptosis, and elevated IL-6/IL-8/TNF-α secretion. These effects were reversed by miR-576-5p overexpression. KLF10 was confirmed as a direct target, showing inverse correlation with miR-576-5p. Overexpression of KLF10 counteracted the protective effects of miR-576-5p, reinstating inflammatory response and apoptosis.
conclusionsmiR-576-5p represents a promising diagnostic biomarker for OA and alleviates disease progression by targeting KLF10, thereby reducing chondrocyte dysfunction. These results offer new insights into miRNA-based therapeutics for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.